Cell state-dependent chromatin targeting in NUT carcinoma.

Autor: Alekseyenko AA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.; Disease Biology Department, Triana Biomedicine, Lexington, MA 02421, USA., Zee BM; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.; Proteomics Department, Cell Signaling Technology, Danvers, MA 01923, USA., Dhoondia Z; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA., Kang H; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA., Makofske JL; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.; Oncology Department, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Kuroda MI; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.

Publikováno v: Genetics [Genetics] 2023 Jul 06; Vol. 224 (3).

Integrated loss- and gain-of-function screens define a core network governing human embryonic stem cell behavior.

Autor: Naxerova K; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.; Center for Systems Biology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA., Di Stefano B; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA., Makofske JL; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA., Watson EV; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA., de Kort MA; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA., Martin TD; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA., Dezfulian M; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA., Ricken D; Center for Systems Biology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA., Wooten EC; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA., Kuroda MI; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA., Hochedlinger K; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA., Elledge SJ; Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.

Publikováno v: Genes & development [Genes Dev] 2021 Nov 01; Vol. 35 (21-22), pp. 1527-1547. Date of Electronic Publication: 2021 Oct 28.

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras .

Autor: Chu SH; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Song EJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Chabon JR; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Minehart J; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Matovina CN; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Makofske JL; Department of Genetics, Harvard Medical School, Boston, MA., Frank ES; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Ross K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Koche RP; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY., Feng Z; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Xu H; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Krivtsov A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Rockville, MD; and., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.

Publikováno v: Blood advances [Blood Adv] 2018 Oct 09; Vol. 2 (19), pp. 2478-2490.